InjectionMEDICAL

OI Research Update from Ultragenyx

As you may be aware, the company Ultragenyx is sponsoring a research study, titled Orbit, to determine the safety and efficacy of setrusumab (UX143), for the treatment of OI. The Phase 2 portion of this study was completed in February with 24 patients and they have announced the interim results. Click here to read the full article.

If you have any questions, please email OIStudyInfo@ultragenyx.com.

Translate »